Total Patents

Top Assignees

Algorithms

91

Cytokinetics (42) All others (2 or 1)

Databases

1,466

Affymetrix (108)

U. California (45)

Agilent Tech. (34)

Nanogen (22)

Sequenom (18)

EGF

765

Sugen (23)

Genentech (16)

U. California (12)

DHHS (12)

Yale (11)

CTLA4

63

Bristol-Myers Squibb (20)

Dana Farber (6)

Repligen (4)

Genetics Inst. Inc. (3)

Pfizer (3)

NF-kB

94

U. California (7)

Bristol-Myers Squibb (6)

Tularik (5)

Ariad (3)

Dalhousie Univ. (3)

NOTE: The assignee is the company or organization assigned ownership on the original patent. Through consolidations, mergers and acquisitions, and other transactions, ownership may change. Private organizations, foundations, and hospitals are distinguished from commercial entities by italics. Government entities are indicated by bold typeface.

TRENDS IN UNIVERSITY LICENSING OF GENOMIC AND PROTEOMIC INVENTIONS

Licensing is the principal means of accessing the use of patented technology, and it occurs under terms that are infinitely varied and complex and whose effects are not straightforward. Thus, whether a patented upstream invention is available for licensing—and under what conditions—is possibly the principal determinant of whether exclusive rights can impede or alternatively, facilitate the conduct of follow-on research. Unfortunately, data on licensing are very limited for two reasons. First, unlike patents, government administrative processes generate information on only some licenses whose representativeness is unknown and for which detailed information may be lacking and not publicly available. Licenses to or by



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement